Genomics & Genetics

Atlas of 10 Million Immune Cells Traces How Disease Variants Reach Genes

Paired chromatin and RNA profiling of blood cells from 1,108 Finnish donors links non-coding variants to specific genes and explains why constrained genes hide their eQTLs.

Anam · Oct 23, 2026 · 8 min read

Research & Development

Ono Licenses Biohaven's IgG Degraders: What the MoDE Platform Does

An $80 million upfront deal brings a new way of clearing autoantibodies to Asia. Here is how the liver-directed degraders work and what the early Graves' disease data do and do not show.

Anam · Oct 22, 2026 · 8 min read

Regulatory Affairs

FDA Expedited IND Pilot Tests Rolling Review for First-in-Human Trials

Applications close 30 October for an FDA pilot that reviews first-in-human IND sections as they are finished, with sponsors paired with outside research institutions.

Anam · Oct 22, 2026 · 9 min read

Medical Devices

FDA Approves Hydrogel Spacer to Curb Scarring After Uterine Adhesion Surgery

Juveena, a gel that sets inside the uterus and clears in two to three weeks, cut adhesion recurrence in a blinded trial. Key figures come from a subgroup and await publication.

Anam · Oct 21, 2026 · 8 min read

Digital Health

Conversational AI Takes Histories Before Real Primary Care Visits

In a Lancet feasibility study at Beth Israel Deaconess, Google's AMIE chatted with 98 urgent care patients before their visits without a single safety stop. It had no control arm and a physician watched every chat.

Anam · Oct 20, 2026 · 8 min read

Clinical Trials

Retatrutide Explained: Trial Results, FDA Filing and the Counterfeit Risk

Lilly's triple agonist has won four phase 3 trials and is due for US filing in early 2027. Until then, anything sold online as retatrutide is unapproved and of unknown quality.

Anam · Oct 19, 2026 · 8 min read

Biotechnology

Base Editing Gives First Clinical Signal in Glycogen Storage Disease Type Ia

Six patients treated with Beam's BEAM-301 needed less cornstarch and fasted longer, but follow-up is short and the lower-dose effect waned.

Anam · Oct 19, 2026 · 9 min read

Drug Discovery

A Synthetic Lethal Drug Reaches Patients Seven Years After Its Target Was Found

The first WRN helicase inhibitor tested in humans held disease stable in three quarters of patients with microsatellite instability tumours, but shrank only one in ten.

Anam · Oct 18, 2026 · 7 min read

Neuroscience

An Enzyme That Rises With Age May Be Part of Why Some Brains Resist Decline

PLA2G2F climbs in ageing neurons, protects memory in mice when boosted, and is most active in people whose cognition survived amyloid pathology.

Anam · Oct 18, 2026 · 7 min read

Research & Development

An Automated Route From Bacterial Genome to Peptide, Without Synthetic DNA

A platform called OSAR assembled 31 of 34 large bacterial gene clusters and produced 29 peptides, turning a months-long bespoke process into a batch workflow.

Anam · Oct 18, 2026 · 7 min read

Regulatory Affairs

FDA Sets Out What It Will Disclose, and What Stays Redacted

The agency's Transparency Roadmap makes rejection letters standing practice and proposes disclosing that applications exist, but most of it remains intention rather than rule.

Anam · Oct 18, 2026 · 7 min read

Medical Devices

Sirolimus-Coated Balloon Beats Plain Angioplasty in First US Randomized Trial

SELUTION4SFA randomized 300 patients with narrowed leg arteries and met both its efficacy and safety endpoints, offering the field an alternative to paclitaxel.

Anam · Oct 18, 2026 · 7 min read